Johnson & Johnsonの医薬品および医療機器ポートフォリオは、腫瘍学、免疫学、外科治療への需要増加を促進する高齢化社会から恩恵を受ける立場にあります。
Johnson & Johnsonは130年以上の事業歴を持つ典型的なブルーチップ株であり、少数の企業しか持たないAAAクレジットレーティングと、実質的にいかなる経済サイクルでも安定性を提供する多角的ヘルスケアビジネスを誇っています。
Johnson & Johnsonは60年以上連続した増配実績を持つヘルスケアの巨人であり、世界市場にわたるリーディング医薬品および医療機器フランチャイズを基盤としています。
Johnson & Johnsonは60年以上連続して年次増配を続けるDividend Kingであり、医薬品および医療機器事業の安定した景気後退耐性のあるキャッシュフローに支えられています。信頼性の高い長期的な配当成長実績が、医療セクターで安定した収益を求める投資家にとってプレミアム配当株としています。
Data updated Feb 15 · Source: Twelve Data
Johnson & Johnson remains one of the most dependable names in healthcare investing. Following its Kenvue consumer health spinoff, JNJ is now a focused pharmaceutical and MedTech company, better positioned to capitalize on aging demographics through oncology, immunology, and surgical innovations.
The stock has surged nearly 57% over the past year, now trading near its 52-week high of $246.35 and well above its 50-day moving average. This rally has stretched the P/E ratio to 32.37"elevated relative to historical norms"raising valuation concerns for new entrants. EPS of $7.52 reflects solid but not exceptional earnings power.
As a Dividend Aristocrat with 60+ consecutive years of increases, JNJ's income reliability is unmatched, though the current yield has compressed due to price appreciation. The pharmaceutical pipeline, including Darzalex and Tremfya, provides meaningful growth catalysts, while MedTech benefits from procedure volume recovery.
Key risks include ongoing talc litigation liabilities, patent cliffs on major drugs, and the premium valuation. The bull case centers on pipeline execution, demographic tailwinds, and defensive positioning during economic uncertainty. A strong core holding, though dollar-cost averaging may be prudent at current levels.
Johnson & Johnson remains a definitive blue-chip holding, recently demonstrating robust momentum as it trades near its 52-week high of $240.94. Following its strategic restructuring to focus on high-growth pharmaceutical and MedTech segments, the stock has surged well above its 50-day moving average. However, the current valuation warrants caution; at a P/E ratio of 31.70, JNJ is trading at a significant premium to its historical range, suggesting that optimistic growth expectations are already priced in. While the company's legendary status as a Dividend King continues to attract income investors seeking stability, the stretched multiple may limit near-term upside. JNJ represents a high-quality defensive play with a fortress balance sheet, but value-conscious investors might prefer to wait for a pullback before adding to positions.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
すべてのトレーダーは頭の中で良さそうに見える戦略を持っています。バックテストは、それが実際に機能するかどうかを調べる方法です。ここは戦略を適切にテストする方法、どのメトリクスが重要か、そしてほとんどのバックテスト結果が本当とは思えないほど良い理由です。
Powered by Rexiew